A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00671216 |
Recruitment Status
:
Completed
First Posted
: May 5, 2008
Last Update Posted
: October 4, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Disease, Chronic Obstructive | Drug: GSK233705 Drug: GW642444 Drug: GSK233705 and GW642444 Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705 and GW642444 as Monotherapies and in Combination in Healthy Subjects. |
Actual Study Start Date : | May 20, 2008 |
Actual Primary Completion Date : | July 7, 2008 |
Actual Study Completion Date : | July 7, 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Period 1
Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
|
Drug: GSK233705
Subjects will receive 200 (mcg) microgram once daily as a single dose
Drug: GW642444
Subjects will receive 50 mcg once daily as a single dose
Other Name: GSK233705
Drug: GSK233705 and GW642444
Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
Drug: Placebo
Placebo matching study medication will be inhaled by subjects
|
Experimental: Period 2
Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
|
Drug: GSK233705
Subjects will receive 200 (mcg) microgram once daily as a single dose
Drug: GW642444
Subjects will receive 50 mcg once daily as a single dose
Other Name: GSK233705
Drug: GSK233705 and GW642444
Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
Drug: Placebo
Placebo matching study medication will be inhaled by subjects
|
Experimental: Period 3
Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
|
Drug: GSK233705
Subjects will receive 200 (mcg) microgram once daily as a single dose
Drug: GW642444
Subjects will receive 50 mcg once daily as a single dose
Other Name: GSK233705
Drug: GSK233705 and GW642444
Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
Drug: Placebo
Placebo matching study medication will be inhaled by subjects
|
Experimental: Period 4
Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
|
Drug: GSK233705
Subjects will receive 200 (mcg) microgram once daily as a single dose
Drug: GW642444
Subjects will receive 50 mcg once daily as a single dose
Other Name: GSK233705
Drug: GSK233705 and GW642444
Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
Drug: Placebo
Placebo matching study medication will be inhaled by subjects
|
- General safety endpoints: measured over 24 hours post dose for all 4 dose periods, heart rate, systolic and diastolic blood pressure, 12- lead ECG and lung function and clinical laboratory safety tests. Adverse events over whole study. [ Time Frame: Up to Day 2 ]
- Blood levels of GW642444, Blood levels of GSK233705, Blood Levels of potassium [ Time Frame: Pre-dose; Day 1- 5, 15 and 30 minutes, 1, 2, 4, 5,6, 8, 12, 16 and 24 hours and Day 2 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- Male or female between 18 and 65 years of age.
- Female subjects must be of non childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophorectomy or postmenopausal
- Male subjects must agree to use one of the contraception methods listed in protocol. This criterion must be followed from the time of the first dose of study medication until 90 days post-last dose.
- BMI within the range 18 - 30 kg/m2 (inclusive).
- Average QTc(B)≤450 msec taken from triplicate assessments at screening.
- No clinically active and relevant abnormality on 12-lead ECG at screening or 24h Holter ECG.
- Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).
- Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
- A signed and dated written informed consent is obtained from the subject
- The subject is capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- Available to complete the study
Exclusion Criteria:
- Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead). 24hr Holter monitoring outside normal limits.
- A history of breathing problems (i.e. history of asthmatic symptomatology, unless asthma in childhood that has now resolved and no longer requires maintenance therapy which should not be an exclusion).
- A mean QTc(B) value at screening >450msec, or an ECG that is not suitable for QT measurements (e.g. LBBB or poorly defined termination of the T wave).
- A history of elevated resting blood pressure or a mean blood pressure higher than 140/90 mmHg at screening.
- A mean heart rate outside the range 40-90 bpm at screening.
- The subject has a positive pre-study drug/alcohol screen. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive test for HIV antibody (if determined by the local SOP's).
- History of high alcohol consumption within 3months of the study defined as:
- an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, (except for simple analgesics eg paracetamol), including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products prior to screening.
- The subject is unable to use the novel dry powder inhaler correctly.
- The subject has a known allergy or hypersensitivity to ipratropium bromide, Tiotropium, atropine and any of its derivatives.
- Any adverse reaction including immediate or delayed hypersensitivity to any β2 agonist or sympathomimetic drug,
- The subject has a known allergy or hypersensitivity to milk protein or the excipients lactose monohydrate and MgSt.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00671216
United Kingdom | |
GSK Investigational Site | |
London, United Kingdom, NW10 7NS |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Additional Information:
Study Data/Documents: Individual Participant Data Set

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register
Publications:
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00671216 History of Changes |
Other Study ID Numbers: |
DB1111509 |
First Posted: | May 5, 2008 Key Record Dates |
Last Update Posted: | October 4, 2017 |
Last Verified: | October 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site. |
URL: | http:// |
Keywords provided by GlaxoSmithKline:
safety pharmacodynamics Muscarinic Receptor Antagonist tolerability healthy subjects |
GS642444 GSK233705 Anticholinergic ß2 agonist pharmacokinetics |
Additional relevant MeSH terms:
Lung Diseases Chronic Disease Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases |
Disease Attributes Pathologic Processes Lung Diseases, Obstructive |